Curbside Consultation in IBD: 49 Clinical Questions, Second Edition

David T Rubin, MD; Sonia Friedman, MD; Francis A Farraye, MD MSc

Question 19: When Is It Appropriate To Switch To Another Biologic Therapy? (continued)

David T. Rubin, MD; Adam E. Mikolajczyk, MD

Biologic therapy is often reserved for moderate to severe patients with Crohn’s disease (CD) or ulcerative colitis (UC) who have failed other conventional therapies. Patients who respond to biologic therapies enjoy an improvement in clinical symptoms; a better quality of life; less disability, fatigue, and depression; and fewer surgeries and hospitalizations. The first biologic therapy approved for CD was infliximab, a chimeric immunoglobulin G1 (IgG1) antibody against tumor necrosis factor alpha (TNF-α), which is now also approved for treatment of moderately to severely active…